4D Molecular Therapeutics FDMT Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's other non-current liabilities?
- 4D Molecular Therapeutics (FDMT) reported other non-current liabilities of $121K in Q1 2026.
- How has 4D Molecular Therapeutics's other non-current liabilities changed year-over-year?
- 4D Molecular Therapeutics's other non-current liabilities decreased by 31.6% year-over-year, from $177K to $121K.
- What is the long-term trend for 4D Molecular Therapeutics's other non-current liabilities?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's other non-current liabilities has grown at a -40.5% compound annual growth rate (CAGR), from $1.85M to $138K.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.